NCT05193409 - A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

October 10, 2022

Study Completion Date

October 17, 2022

Conditions

Social Anxiety Disorder

Interventions

DRUG

225 mg BNC210

DRUG

675 mg BNC210

DRUG

Placebo

Trial Locations (15)

11229

PREVAIL Study Clinical Trial Site, Brooklyn

28211

PREVAIL Study Clinical Trial Site, Charlotte

30030

PREVAIL Study Clinical Trial Site, Decatur

33016

PREVAIL Study Clinical Trial Site, Miami Lakes

33122

PREVAIL Study Clinical Trial Site, New Haven

PREVAIL Study Clinical Trial Site, Miami

33319

PREVAIL Study Clinical Trial Site, Lauderhill

45212

PREVAIL Study Clinical Trial Site, Cincinnati

66208

PREVAIL Study Clinical Trial Site, Prairie Village

84020

PREVAIL Study Clinical Trial Site, Draper

90210

PREVAIL Study Clinical Trial Site, Beverly Hills

91204

PREVAIL Study Clinical Trial Site, Glendale

91316

PREVAIL Study Clinical Trial Site, Encino

02114

PREVAIL Study Clinical Trial Site, Boston

08540

PREVAIL Study Clinical Trial Site, Princeton